论文部分内容阅读
目的探讨非小细胞肺癌综合治疗的标准及疗效。方法对1991年至1999年底手术切除的812例Ⅲa期非小细胞肺癌(NSCLC)的治疗结果进行分析。同时,将全组中326例综合治疗与486例单纯手术病例进行对比。结果全组5年生存率16.4%,其中综合治疗组23.5%,单纯手术组10.2%。综合治疗组5年生存率中鳞癌占27.6%,腺癌23.4%;单纯手术组5年生存率中鳞癌占15.2%,腺癌9.9%。结果显示:综合治疗组生存率高于单纯手术组。结论多学科综合治疗应成为中、晚期NSCLC的标准治疗方式,并且根据不同TNM、病理类型选择不同治疗组合。
Objective To investigate the standard and curative effect of comprehensive treatment of non-small cell lung cancer. Methods 812 cases of stage Ⅲ a non-small cell lung cancer (NSCLC) surgically resected from 1991 to the end of 1999 were analyzed. At the same time, 326 cases of comprehensive treatment in the whole group and 486 cases of simple surgery were compared. Results The 5-year overall survival rate was 16.4%, of which 23.5% in the comprehensive treatment group and 10.2% in the simple operation group. The 5-year survival rate of the comprehensive treatment group was 27.6% for squamous cell carcinoma and 23.4% for adenocarcinoma. The 5-year survival rate in the simple operation group was 15.2% in squamous cell carcinoma and 9.9% in adenocarcinoma. The results showed that the survival rate of the comprehensive treatment group was higher than that of the simple operation group. Conclusion Multidisciplinary comprehensive treatment should be the standard treatment for moderate and advanced NSCLC, and different treatment combinations should be selected according to different TNM and pathological types.